Institutional Ownership Adaptimmune Therapeutics PLC (ADAP)
This table provides information about the institutional ownership of Adaptimmune Therapeutics PLC (ADAP). We have compiled data on the 70 institutions that hold shares in the stock, with a total of 116 Million shares, which have been reported (via 13F filing form) to have a value of $4.64 Million.
| Holding | Report Date | shares Held | Holding Value (Reported) | Last Trade | Trade History |
|---|---|---|---|---|---|
|
Lindbrook Capital, LLC
|
May 05, 2025 Q1 2025 |
4,610
shares
|
$184
0.0% of portfolio
|
Q4 2024
Reduced 4.89%
|
|
|
Cibc Private Wealth Group, LLC
|
May 14, 2025 Q1 2025 |
3,023
shares
|
$120
0.0% of portfolio
|
Q2 2024
Reduced 96.06%
|
|
|
Barclays PLC
London, X0 |
Aug 14, 2025 Q2 2025 |
2,534
shares
|
$101
0.0% of portfolio
|
Q2 2025
Reduced 94.94%
|
|
|
Sandy Spring Bank
|
May 12, 2025 Q1 2025 |
1,050
shares
|
$42
0.0% of portfolio
|
Q3 2023
New holding
|
|
|
Plante Moran Financial Advisors, LLC
|
Aug 05, 2025 Q2 2025 |
925
shares
|
$37
0.0% of portfolio
|
Q3 2024
New holding
|
|
|
Raiffeisen Bank International Ag
Vienna, C4 |
Aug 11, 2025 Q2 2025 |
907
shares
|
$36
0.0% of portfolio
|
Q4 2024
New holding
|
|
|
Garde Capital, Inc.
Seattle, WA |
Jul 03, 2025 Q2 2025 |
750
shares
|
$30
0.0% of portfolio
|
Q2 2025
New holding
|
|
|
Bryn Mawr Trust CO
Bryn Mawr, PA |
Jul 28, 2025 Q2 2025 |
604
shares
|
$24
0.0% of portfolio
|
Q3 2024
New holding
|
|
|
Carmichael Hill & Associates, Inc.
|
Oct 29, 2024 Q3 2024 |
525
shares
|
$21
0.0% of portfolio
|
Q1 2022
Added 50.0%
|
|
|
High Mark Wealth Management LLC
|
Jul 21, 2025 Q2 2025 |
287
shares
|
$11
0.0% of portfolio
|
Q3 2023
Reduced 77.38%
|
|
|
Parallel Advisors, LLC
|
Jul 07, 2025 Q2 2025 |
250
shares
|
$10
0.0% of portfolio
|
Q4 2024
Reduced 96.52%
|
|
|
Transce3nd, LLC
Kyle, TX |
Aug 13, 2025 Q2 2025 |
175
shares
|
$7
0.0% of portfolio
|
Q4 2024
New holding
|
|
|
Northwestern Mutual Wealth Management CO
|
Aug 13, 2025 Q2 2025 |
153
shares
|
$6
0.0% of portfolio
|
Q2 2025
New holding
|
|
|
Exane Derivatives
|
Jul 12, 2022 Q2 2022 |
121
shares
|
$4
0.0% of portfolio
|
Q3 2018
Reduced 99.1%
|
|
|
Investors Research Corp
|
Jul 07, 2025 Q2 2025 |
100
shares
|
$4
0.0% of portfolio
|
Q3 2023
Reduced 50.0%
|
|
|
Koesten, Hirschmann & Crabtree, Inc.
Overland Park, KS |
Aug 15, 2025 Q2 2025 |
47
shares
|
$1
0.0% of portfolio
|
Q2 2025
New holding
|
|
|
Td Waterhouse Canada Inc.
Toronto, A6 |
Aug 11, 2025 Q2 2025 |
14
shares
|
$0
0.0% of portfolio
|
Q3 2024
New holding
|
|
|
Sbi Securities Co., Ltd.
Tokyo, M0 |
Aug 07, 2025 Q2 2025 |
10
shares
|
$0
0.0% of portfolio
|
Q1 2025
New holding
|
|
|
Concourse Financial Group Securities, Inc.
Birmingham, AL |
Aug 12, 2025 Q2 2025 |
0
shares
|
$0
100.0% of portfolio
|
Q2 2025
New holding
|